We are assessing a new treatment, ANX1502, for individuals with Primary Cold Agglutinin Disease. This study aims to understand its safety and how it affects the condition.
Health conditions and diseases that the clinical trial is designed to study and treat.
Cold Agglutinin Disease (CAD) is a rare autoimmune disorder where the body produces antibodies that cause red blood cells to clump together in cold temperatures, leading to symptoms like fatigue, jaundice, and cold-induced pain.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.